A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2014
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 15 Oct 2008 Actual start date changed from Sep 20054 to Oct 2005 as reported by ClinicalTrials.gov.
- 15 Jan 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 23 Feb 2007 New trial record.